Exclusive: EU to propose delay to medical device law amid supply worries

Exclusive: EU to propose delay to medical device law amid supply worries

LONDON, Dec 8 (Reuters) – The EU Health Commissioner will on Friday suggest extending the deadline for corporations to comply with a new regulation regulating healthcare products, she told Reuters on Thursday as health professionals alert the laws is creating shortages of lifesaving equipment.

Stella Kyriakides advised Reuters that troubles in utilizing the regulation had been threatening provides of crucial units, such as catheters used for surgical procedures on newborns with heart problems.

“Our clients expect that medical devices are protected and of maximum high quality. We have manufactured vital progress to set in position new necessities for client basic safety, but issues however remain,” stated Kyriakides in created emailed reviews to Reuters.

“This is why, to mitigate any quick-term dangers, we will tomorrow announce an extension of the transition interval to mitigate any hazard of shortages.”

Kyriakides will make the proposal at a assembly of EU wellbeing ministers on Friday. She mentioned in parliament previous month she was looking at amendments.

A Fee supply reported the extension will have to have an amendment to the regulation. Any authorized modifications would require to be authorised by the Council and Parliament.

Kyriakides did not comment on how extensive the extension would be for.

The Health-related Units Regulation (MDR) arrived into effect final yr and was released soon after the 2010 scandal of exploding breast implants produced by a French corporation that exploited loopholes to promote faulty products and solutions at earnings.

It has much more stringent prerequisites and greater protection benchmarks than the directive it replaced.

Under the new regulation, all healthcare equipment, from implants and prosthetics to blood glucose meters and pacemakers sold in the EU will have to be re-qualified by May possibly 2024.

A dozen doctors and brands interviewed by Reuters say materials of some items are managing reduced even prior to the 2024 deadline.

Which is because certificates which very last for 5 a long time underneath the previous program are expiring and organizations are struggling to get new ones underneath the new legislation. They say the new certification course of action is sluggish, cumbersome and pricey.

“From the standpoint of medical doctors, the situation is becoming far more and a lot more stressing. We are already looking at shortages of some important medical products, and in quite a few cases option equipment are lacking,” Christiaan Keijzer, president of the Standing Committee of European Medical practitioners (CPME), informed Reuters.

He mentioned that health care associations across Europe have claimed complications with the provide of surgical devices, particularly in paediatrics, orthopaedics and cardiology, as perfectly as other products these kinds of as binocular endoscopes, silicone adhesives and blood collection things.

Facts launched by the Fee in a assertion this week in advance of Friday’s conference highlights the situation.

Brands have submitted programs for around 8,000 devices, but a lot less than 2,000 have been accredited.

At that speed, only 7,000 certificates below the new method will be issued by the May 2024 deadline, the Commission claimed.

The Commission mentioned there are about 23,000 certificates below the previous system which will expire by May well 2024 with no an extension. About 4,300 of those people will expire upcoming calendar year, it explained.

Certificates go over various units, earning it difficult to estimate the complete amount of products potentially impacted.

Reporting by Maggie Fick enhancing by Josephine Mason and Elaine Hardcastle

Our Requirements: The Thomson Reuters Belief Rules.

Global Wireless Medical Device Connectivity Market to 2027 – Featuring Baxter International, Bridge-Tech Medical, Cisco Systems and Masimo Among Others – ResearchAndMarkets.com

Global Wireless Medical Device Connectivity Market to 2027 – Featuring Baxter International, Bridge-Tech Medical, Cisco Systems and Masimo Among Others – ResearchAndMarkets.com

DUBLIN–(Organization WIRE)–The “Wi-fi Healthcare Machine Connectivity: Worldwide Marketplaces” report has been included to ResearchAndMarkets.com’s presenting.

In this report, wireless medical unit connectivity has been segmented based on supplying, wireless connectivity form, end consumer, software, and geography.

Companies Outlined

  • Baxter International Inc.
  • Bridge-Tech Professional medical Inc.
  • Capsule Systems Inc. (Koninklijke Philips N.V.)
  • Cisco Units, Inc.
  • Digi Intercontinental Inc.
  • Ge Health care (Standard Electrical Corporation)
  • Iatric Systems Inc. (Harris Health care Group)
  • Infosys Ltd.
  • Lantronix Inc.
  • Masimo Corp.
  • Medtronic plc
  • Minnetronix Health-related Inc.
  • Oracle Corp.
  • Qualcomm Inc.
  • Silex Technological know-how The usa Inc.
  • Stryker
  • Te Connectivity Ltd.
  • Wipro Ltd.

The report offers an overview of the world wide wireless healthcare system connectivity current market and analyzes the sector trends. It considers 2021 as the foundation yr of 2021 and gives estimates for 2022 to 2027. Revenue forecasts from the period of time for segmentation primarily based on the presenting, wireless connectivity type, application, stop-consumer, and geography have been believed with values derived from manufacturers’ overall revenues.

The report also involves a section on the key gamers in the industry. Even more, it points out the important drivers, competitive landscape, and latest developments for wi-fi clinical device connectivity solutions. The report concludes with a in-depth target on the wi-fi healthcare unit connectivity landscape and includes in-depth profiles of the big players running in the international wireless clinical device connectivity market.

Clinical product connectivity refers to maintaining connections among healthcare gear. It removes the possibility of human mistake. As a result, knowledge can be transferred between devices additional promptly and precisely. The scope of the review consists of only wi-fi medical unit connectivity methods from the a few offered connectivity styles: wired, wireless, and hybrid. These remedies are greatly applied for disorders that call for continual monitoring, which include diabetic sufferers, most cancers clients, asthmatics, and so forth.

Report Features

  • 49 facts tables and 30 supplemental tables
  • A complete overview and up-to-day examination of the world marketplace for wi-fi professional medical connectivity systems
  • Analyses of the international sector developments, with historic marketplace revenue facts for 2021, estimates for 2022, forecasts for 2023 and 2025, and projections of compound yearly expansion fees (CAGRs) through 2027
  • Estimation of the true current market dimensions and revenue forecast for wireless medical connectivity in USD tens of millions, and corresponding market place share investigation primarily based on answers supplying, wireless connectivity variety, application, end user, and location
  • In-depth facts (specifics and figures) about key market place dynamics, options and difficulties, engineering enhancements, price chain assessment, and aggressive environment of the leading current market gamers
  • Coverage of the technological, economic, and business considerations of the global wi-fi health care connectivity market, with analyses and development forecasts by 2027
  • Highlights of the rising technological know-how developments, possibilities and gaps estimating the existing and upcoming demand from customers for wi-fi health-related connectivity methods, and effects of COVID-19 on the progress of this sector
  • Identification of the corporations greatest positioned to satisfy this demand owing to or in conjunction with their proprietary systems, solution launches, M&A promotions, and other current market strategic strengths

Crucial Subjects Included:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Sector Overview

3.1 Overview

3.1.1 Rewards of Wireless Health care Product Connectivity

3.1.2 Applicational Locations for Wireless Health care Unit Connectivity

3.1.3 Wireless Health care Machine Connectivity Ecosystem

3.2 Expectations for Wi-fi Medical Machine Connectivity

3.3 Rules for Wi-fi Professional medical Gadget Connectivity

3.4 Porter’s Five Forces Analysis

3.4.1 Power of Suppliers

3.4.2 Electrical power of Buyers

3.4.3 Menace of Substitutes

3.4.4 Danger of New Entrants

3.4.5 Degree in Opposition

3.5 Foreseeable future of the Market place for Wireless Health-related Device Connectivity

3.6 Effect of Covid-19 on the Industry for Wireless Clinical Gadget Connectivity

3.6.1 Post-Covid-19 Pandemic State of affairs

Chapter 4 Sector Dynamics

4.1 Market place Motorists

4.1.1 Escalating Growing older Inhabitants

4.1.2 Growing Cyber-Assaults on Health care Institutions

4.1.3 Expanding Adoption of Wearable Equipment and Hies in Healthcare

4.1.4 Healthcare Unit Connectivity Aids in Affected person Basic safety and Details Analytics

4.2 Marketplace Restraints

4.2.1 Deficiency of Technological Awareness in Rural Areas

4.2.2 Mounting Healthcare Fraud

4.3 Market Options

4.3.1 Amplified Help From Infectious Disorders

4.3.2 Increasing Adoption of Connectivity Platforms

4.3.3 Increasing Collaboration Amongst Current market Players

4.4 Market Challenges

4.4.1 Absence of Regular Interfaces

Chapter 5 Market Breakdown by Providing

5.1 Overview

5.2 Components

5.2.1 Wireless Telemetry

5.3 Software package

5.4 Products and services

Chapter 6 Industry Breakdown by Wi-fi Connectivity Style

6.1 Overview

6.2 Wi-Fi

6.3 Bluetooth

6.4 Zigbee

6.5 Other folks

Chapter 7 Market Breakdown by Conclude-consumer

7.1 Overview

7.2 Property Health care

7.3 Hospitals

7.4 Others

Chapter 8 Market Breakdown by Software

8.1 Overview

8.2 Essential Indications and Affected individual Monitors

8.3 Anesthesia Machines and Ventilators

8.4 Infusion Pumps

8.5 Other folks

Chapter 9 Sector Breakdown by Area

Chapter 10 Competitive Landscape

10.1 Sector Rating

10.2 Strategic Analysis

10.2.1 Merchandise Launches, Expansions, and Partnerships

Chapter 11 Firm Profiles

Chapter 12 Appendix: Acronyms

For more information and facts about this report check out https://www.researchandmarkets.com/r/rrrwj6

15 Biggest Medical Device Companies in the World

15 Biggest Medical Device Companies in the World

In this article, we will take a look at the 15 biggest medical device companies in the world. If you want to skip our introduction to the industry, then take a look at 5 Biggest Medical Device Companies in the World.

The medical device market comprises companies that manufacture equipment used in diagnosing, treating and surveillance medical disorders. The market for medical devices is changing dramatically. The complicated patient demands and the COVID-19 pandemic encouraged businesses to innovate and produce new creative solutions, and the medical devices industry continued to see exceptional growth in 2020. The global market for medical equipment was worth roughly $456.8 billion in 2020, with a CAGR (Compound annual growth rate) of 3.5{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} from 2015. This market is expanding due to the rise in demand for high-tech medical items. There was a fall in the number of diagnoses for various diseases including cancer and TB among others as a result of the COVID-19 epidemic. However, as the pandemic wanes off, the medical device industry is continuing to get back on its growth trajectory.

The frequency of chronic diseases will significantly affect the global medical device market beyond 2022. This encourages the employment of ever-improving technology tools for early disease detection and the creation of intelligent equipment like 3D printing, robots, and the internet of things. As a result, the market for medical device technology will expand at a CAGR of 4.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} from 2022 to 2027. Growth is predicted from $465.5 billion in 2022 to $591.3 billion in 2027.

Some of the major players in the medical device industry are Boston Scientific Corporation (NYSE:BSX), Medtronic plc (NYSE:MDT), and Abbott Laboratories (NYSE:ABT).

smart.art/Shutterstock.com

Our Methodology

The list includes firms that manufacture medical equipment to treat illnesses. Stocks are presented in order of market capitalization. To offer some different perspective, the analyst ratings of these companies and the most recent information about them are also reviewed. Finally, the number of hedge funds with positions in each company was determined using data from 920 elite hedge funds that Insider Monkey analyzed in the third quarter of 2022.

Biggest Medical Device Companies in the World

15. Globus Medical, Inc. (NYSE:GMED)

Market Cap as of November 18: $6.84 B

 

Number of Hedge Fund Holders: 20

Globus Medical, Inc. (NYSE:GMED) sells healthcare products and services to hospitals, doctors’ offices, and surgical centers. Globus Medical, Inc. (NYSE:GMED) shares have offered investors more than 6.71{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} in returns over the past month as of November 18.

Globus Medical, Inc. (NYSE:GMED) is rated 15th among the world’s biggest medical device companies, with a market value of $6.84 billion. On October 17, Barclays analyst Matt Miksic initiated coverage of Globus Medical, Inc. (NYSE:GMED), assigning the stock an ‘Overweight’ rating and a $69 price target.

At the end of the third quarter, 20 hedge funds in Insider Monkey’s database of 920 funds held stakes in Globus Medical, Inc. (NYSE:GMED) compared to 21 funds in the second quarter. Like Boston Scientific Corporation (NYSE:BSX), Medtronic plc (NYSE:MDT), and Abbott Laboratories (NYSE:ABT), Globus Medical, Inc. (NYSE:GMED) is one of the elite medical device stocks to monitor.

Here is what Madison Small Cap Fund has to say about Globus Medical, Inc. (NYSE:GMED) in its Q4 2020 investor letter:

“Healthcare continued its streak of underperformance in the fourth quarter. The biotech industry component of the Russell 2000 was up 34{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} for the quarter and 53{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} for the year. While we have become more open to investing in this space where appropriate, we prefer molecular diagnostics given less regulatory risk and better revenue diversification. With the new administration comes a shift in healthcare philosophy. We believe that further access to care and coverage expansion will benefit some parts of the sector. However, the risk of further reimbursement cuts, particularly in pharmaceuticals, will bear monitoring.….” (Click here to read the full text)

14. Penumbra, Inc. (NYSE:PEN)

Market Cap as of November 18: $7.34 B

 

Number of Hedge Fund Holders: 27

Penumbra, Inc. (NYSE:PEN) is a medical device company that manufactures products for the neurovascular and peripheral vascular industries. Penumbra, Inc. (NYSE:PEN) announced the launch of the latest REAL y-Series on November 15. Since it employs a whole body picture, it is the first hands-free, non-tethered virtual reality rehabilitation platform that can treat both the upper and lower extremities.

RBC Capital analyst Brandon Henry boosted his price objective on Penumbra, Inc. (NYSE:PEN) to $215 from $195 on November 14 and reiterated an ‘Outperform’ rating on the stock. According to the analyst, the Q3 results caused the stock to rise 13{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} in November.

Among the hedge funds tracked by Insider Monkey, 27 reported owning stakes worth $549.89 million in Penumbra, Inc. (NYSE:PEN) at the end of September 2022, compared to 21 funds in the prior quarter worth $224.66 million. Rock Springs Capital Management is the most notable stakeholder of the company, with nearly 476,000 shares worth $90.25 million.

ClearBridge Investments mentioned Penumbra, Inc. (NYSE:PEN) in its Q4 2021 investor letter. Here is what the fund said:

“Our aversion toward early-stage biotech proved productive as did our approach of emphasizing the enablers and selected, profitable medical technology companies. Strong contributors during the fourth quarter included Penumbra, a developer of stents and related products to treat aneurysms that saw it shares recover from a product recall earlier in the year.”

13. ShockWave Medical, Inc. (NASDAQ:SWAV)

Market Cap as of November 18: $8.96 B

 

Number of Hedge Fund Holders: 34

ShockWave Medical, Inc. (NADAQ:SWAV) is focused on designing and marketing products that will transform how calcified cardiovascular disease is treated. Calcified plaque is treated using the business’s intravascular lithotripsy method.

On November 8, Wells Fargo analyst Larry Biegelsen raised his price target on ShockWave Medical, Inc. (NADAQ:SWAV) from $255 to $300 and reiterated an ‘Overweight’ rating on the stock in light of the company’s improved 2022 projection and Q3 outperformance.

According to Insider Monkey’s data, 34 hedge funds were long ShockWave Medical, Inc. (NADAQ:SWAV) at the end of the third quarter of 2022, compared to 27 funds in the prior quarter. Jim Simons’ Renaissance Technologies held the biggest stake in the company, with approximately 322,700 shares valued at $89.73 million.

Artisan Partners mentioned ShockWave Medical, Inc. (NADAQ:SWAV) in its Q3 2022 investor letter, outlining that:

“ShockWave Medical, Inc. (NASDAQ:SWAV) is an early stage medical device company developing and commercializing products to treat calcified cardiovascular disease. The company’s recent quarter of +116{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} YoY revenue growth was well ahead of expectations. The beat was driven primarily by the C2 coronary intravascular lithotripsy catheter—used to break up hard materials that restrict blood flow to the heart—as it makes solid progress capturing share from stenting cases. We believe the profit cycle opportunity for C2 is meaningful given its large addressable market ($4 billion).”

12. Bruker Corporation (NASDAQ:BRKR)

Market Cap as of November 18: $9.74 B

 

Number of Hedge Fund Holders: 28

Bruker Corporation (NASDAQ:BRKR) manufactures scientific equipment and diagnostic tests for the life sciences, pharmaceutical, and biotechnology sectors. The company’s four operational sectors are Bruker BioSpin Group, Bruker Calid Group, Bruker Scientific Instruments Nano, and Bruker Energy & Supercon Technologies. On October 21, UBS analyst John Sourbeer initiated coverage of Bruker Corporation (NASDAQ:BRKR), rating the stock as ‘Buy’ and a price objective of $70.

On November 14, Bruker Corporation announced the execution of a formal agreement to acquire all of Neurescence Inc.’s shares for concurrent multi-region, optical functional neuroimaging. The biotechnology company Neurescence Inc. is a creative manufacturer of portable fiber-bundle multi-scope.

At the end of the third quarter, 28 hedge funds in Insider Monkey’s database held stakes in Bruker Corporation (NASDAQ:BRKR), compared to 25 funds in the second quarter. Millennium Management, with 1.44 million shares, is the most significant stakeholder in the company.

11. Smith & Nephew plc (NYSE:SNN)

Market Cap as of November 18: $11.01 B

 

Number of Hedge Fund Holders: 12

Smith & Nephew plc (NYSE:SNN) develops, produces, and sells orthopedic devices, arthroscopic and sports medicine technology, and wound-care products. The ROCE for Smith & Nephew plc (NYSE:SNN) stands at 9.0{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}. Although it’s a poor return in absolute terms, it’s close to the 9.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} industry average for medical equipment.

Robert Davies, an analyst at Morgan Stanley, initiated coverage of Smith & Nephew plc (NYSE:SNN) on October 18, rating the stock as an ‘Equal Weight’ and a 1,229 GBp price objective.

According to the third quarter database of Insider Monkey, 12 hedge funds were bullish on Smith & Nephew plc (NYSE:SNN). The stakes of these funds are valued at $92.13 million. Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital is the most prominent position holder in the company, with approximately 1.74 million shares worth $40.31 million.

Here is what Palm Valley Capital Management has to say about Smith & Nephew plc (NYSE:SNN) in its Q3 2022 investor letter:

“We bought Smith & Nephew plc (NYSE:SNN) toward the end of the quarter. Smith & Nephew is a Londonbased medical device company that specializes in knee and hip replacements, sports medicine, and wound management. We purchased the ADR, which has declined meaningfully (-31{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} year-to-date) along with the British pound. While Smith & Nephew’s stock is priced in pounds, its revenues are in other major currencies, such as the dollar, euro, and yen. In 2021, 51{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of its revenues were generated in the United States, while 31{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} were in other developed markets. We believe Smith & Nephew is a high-quality business that generates above average profit margins and abundant free cash flow. We were pleased the turmoil in the British pound provided us with the opportunity to purchase its shares at a discount to our calculated valuation.”

10. Bio-Rad Laboratories, Inc. (NYSE:BIO)

Market Cap as of November 18: $11.75 B

 

Number of Hedge Fund Holders: 45

Bio-Rad Laboratories, Inc. (NYSE:BIO) currently has an $11.75 billion market capitalization and is placed tenth on the list of the 15 biggest medical device companies in the world. The company is located in Hercules, California, and it develops, produces, and markets clinical diagnostics and life sciences products and solutions.

On August 24, Credit Suisse analyst Dan Leonard initiated coverage of Bio-Rad Laboratories, Inc. (NYSE:BIO), assigning the stock an ‘Outperform’ rating and a $715 price target. The analyst had positive opinions on both the digital PCR, or dPCR, product cycle and the company’s forecasts for margin growth.

By the end of the third quarter, Insider Monkey found Bio-Rad Laboratories, Inc. (NYSE:BIO) to be a part of 45 hedge fund portfolios, compared to 43 positions in the previous quarter. Israel Englander’s Millennium Management is the company’s largest stakeholder, with 458,645 shares worth over $191.32 million.

9. Align Technology, Inc. (NASDAQ:ALGN)

Market Cap as of November 18: $15.23 B

 

Number of Hedge Fund Holders: 38

Align Technology, Inc. (NASDAQ:ALGN) is the maker of transparent dental aligners. In addition, the firm makes intraoral scanners (iTero), which are utilized in orthodontic therapy and restorative dental operations. According to the third quarter database of Insider Monkey, 38 hedge funds were long Align Technology, Inc. (NASDAQ:ALGN), compared to 33 funds in the prior quarter.

On October 27, Baird analyst Jeff Johnson maintained an ‘Outperform’ rating on Align Technology, Inc. (NASDAQ:ALGN) and reduced his price objective to $260 from $310. The analyst attributed the company’s issues to this year’s economic turbulence and last year’s unfavorable stimulus-spending comparison.

Brian Bares’ Bares Capital Management is the most prominent position holder in Align Technology, Inc. (NASDAQ:ALGN), with approximately 913,324 shares worth $189.16 million.

Polen Capital mentioned the company in its Q2 2022 investor letter. Here is what the fund said:

“Align Technology shares declined significantly during the second quarter when management reported a meaningful deceleration in growth. Management cited a host of challenges, including COVID19 impacts, especially in China with restrictions and lockdowns under their zero-COVID policy, a weaker economic environment, inflationary pressures, supply chain disruptions, and the war in Ukraine, to name a few. Tough comparisons were also a reality— Invisalign case starts in 1Q22 were roughly flat, having lapped the 66{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} growth from the prior year. It’s not completely surprising that growth is slowing on such tough comparisons, but the company’s shares declined on the news..….” (Click here to read the full text)

8. Abiomed, Inc. (NASDAQ:ABMD)

Market Cap as of November 18: $16.99 B

 

Number of Hedge Fund Holders: 34

Abiomed, Inc. (NASDAQ:ABMD) is a company that conducts research, develops, and sells medical devices that help or take the place of a failing heart’s pumping action. The company offers the Impella CP, a tool used by cardiac surgeons and interventional cardiologists to help patients in cath labs, and the Impella 2.5, a percutaneous micro heart pump with an inbuilt motor and sensors.

Following the declaration that Johnson & Johnson (NYSE:JNJ) has acquired all the outstanding shares of Abiomed, Inc. (NASDAQ:ABMD), Morgan Stanley analyst Cecilia Furlong upgraded the stock of Abiomed (ABMD) to ‘Equal Weight’ on November 2 from ‘Underweight’ with a $380 price target, up from $235.

Hedge fund interest in Abiomed, Inc. (NASDAQ:ABMD) increased in September 2022. 34 hedge funds in our database reported owning stakes in the company at the end of the third quarter, compared to 30 in the previous quarter.

7. Insulet Corporation (NASDAQ:PODD)

Market Cap as of November 18: $20.66 B

 

Number of Hedge Fund Holders: 39

Insulet Corporation (NASDAQ:PODD) manufactures insulin delivery devices for people with diabetes. It provides a wireless companion, portable personal diabetes management, and the Omnipod System. This self-adhesive disposable tubeless Omnipod gadget is worn on the body and is sustainable for up to three days at a time.

Following Insulet Corporation (NASDAQ:PODD)’s Q3 earnings beat and revised FY22 projection, BTIG analyst Marie Thibault increased his price objective on the stock to $320 from $285 on November 11 and retained a ‘Buy’ rating. In addition, as of the end of the third quarter, 39 hedge funds tracked by Insider Monkey had owned stakes in Insulet Corporation (NASDAQ:PODD), compared to just 34 funds in the previous quarter.

In its Q1 2022 investor letter, ClearBridge Investments mentioned Insulet Corporation (NASDAQ:PODD). Here is what the firm said:

“Health care has always been a core foundation of the portfolio and we have been diversifying our health care exposure to include services and solutions beyond our traditional overweight to biopharmaceuticals and managed care. We first purchased Insulet Corporation (NASDAQ:PODD), a leading provider of insulin pumps for diabetes patients, in the fourth quarter of 2021, and we have aggressively added to the position since then. The company is currently the only meaningful manufacturer of patch pumps, the preferred form factor for many patients as compared to traditional tubed pumps. We believe Insulet has a long runway for growth given its large and underpenetrated market, which is only one-third penetrated in Type 1 diabetes and low-single-digit penetrated in the insulin- intensive Type 2 diabetes population. Additionally, we see the launch of the company’s next generation offering, Omnipod 5, which received FDA clearance in January, as an accelerant to growth. Insulet has strong gross margins and is profitable today, though we still see room for significant operating margin expansion ahead.”

6. Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Market Cap as of November 18: $23.53 B

 

Number of Hedge Fund Holders: 37

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) develops, produces, and sells orthopedic reconstructive implants, orthopedic supplies and surgical equipment. The majority of the reconstructive market in the US, Europe, and Japan is presently owned by Zimmer as a result of the acquisitions of Centerpulse in 2003 and Biomet in 2015.

On November 3, Citi analyst Joanne Wuensch retained a ‘Neutral’ rating on the shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) and cut her price objective from $119 to $116. Wuensch claimed that the orthopedic industry was among the most hit by the pandemic since elective procedures were put off and recovery was challenging.

At the end of the third quarter of this year, 37 hedge funds tracked by Insider Monkey had stakes in Zimmer Biomet Holdings, Inc. (NYSE:ZBH), compared to 41 funds in the previous quarter. Boston Scientific Corporation (NYSE:BSX), Medtronic plc (NYSE:MDT) and Abbott Laboratories (NYSE:ABT) are met by Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in our list of biggest medical devices stocks.

In its Q4 2021 investor letter, Ariel Investments mentioned Zimmer Biomet Holdings, Inc. (NYSE:ZBH). Here is what the fund said:

“A reopening of the global economy with a reduction in the severity of the pandemic has led us to invest in companies that would perform well with an end to Covid restrictions such as canceled sports and entertainment events or companies that would benefit from pent-up demand for consumer products. Healthcare holdings such as Zimmer Biomet Holdings Inc. (ZBH) saw demand for their “elective” healthcare services decline sharply as hospitals lost capacity for non-essential surgeries or orthotics. We believed those companies should see a rebound in their business as cases decline. Unfortunately, two new Covid variants turned this theme from a tailwind to a headwind in the second half of the year. First, Delta then Omicron sent Covid cases higher and both companies saw their businesses slow again. Zimmer’s stock lost -13.04{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} in the fourth quarter. As we write, we believe Omicron cases could be nearing a peak which would allow our thesis to better play out this year.”

 

Click to continue reading and see 5 Biggest Medical Device Companies in the World.

 

Suggested articles:

Disclosure: None. 15 Biggest Medical Device Companies in the World is originally published on Insider Monkey.

Medical device sterilizers seek alternatives to ethylene oxide

Medical device sterilizers seek alternatives to ethylene oxide

Alex Kacik: Each surgical procedure calls for a sterile instrument or product. Quite a few companies that sterilize medical solutions have been working with a chemical referred to as ethylene oxide, which has been connected with some major environmental and well being relevant impacts. How will the healthcare market adjusts amid these fears? Welcome the Fashionable Healthcare’s Further than the Byline, which offers a behind the scenes glimpse into our reporting. My identify is Alex Kacik, senior operations reporter, and I’m joined by Kara Hartnett, overall health [disparities] reporter. Thanks for coming on Kara.

Kara Hartnett: Yeah, thanks for possessing me.

Alex Kacik: All ideal, Kara, you just came out with a truly attention-grabbing story about ethylene oxide and normally referred to as EtO. Healthcare business appears to be to be at somewhat of a crossroads emissions from sterilization crops applying that chemical have been joined to cancer. But new limitations on ethylene oxide would need a large restructuring of the sterilization marketplace and pinch the healthcare source chain. Notify us a lot more about this concern and what you learned.

Kara Hartnett: Yeah, Alex, it really is a big conundrum for the business. And it can be receiving amplified visibility and pressure from communities wherever these sterilizers work, and now from federal organizations that are planning to release a rule on it. So I guess the initial issue to know is that ethylene oxide was specified a human carcinogen by the Environmental Defense Agency in 2016. It can be a colorless gas, so you can’t scent it. But if you’re exposed to it, you could get ill. So shorter term, we’re talking items like coughing, nausea, dizziness, headache, and in extended time period, it’s recognised to bring about cancer. So in the healthcare industry, producers use it in just their sterilization services to thoroughly clean their items. It is really crucial for infection management, with health-related products like like catheters, pacemakers, and issues like surgical kits. But they’re also made use of in other industries to clean issues like spice or make degreaser. And then if you smoke cigarettes, you can find ethylene oxide there. So when the EPA designation came out, it also came with a ton of community outreach. And when folks obtained word that some of these services ended up working in their communities, it prompted a good deal of backlash. So no new polices came from the EPA at that time, but states actually begun investigating these vegetation and putting in their very own polices. So the point out by point out investigations truly helped uncover the risk of emissions created by these amenities. And they also put on total exhibit the very form of fragile mother nature of the health care supply chain. And then this was all taking place in 2019. Mind you, so in advance of the pandemic and all of the difficulties that arrived with that. But as sterilizers, had been possessing to shut down or disrupt operations to include new emission controls, amid these states using action, the Fda was also putting out warnings of merchandise delays and shortages. And so team buying companies had been owning to function with producers to type of recoup that provide. And point out and federal agencies ended up owning helped coordinate the broader offer chain. And from what I can have an understanding of, amid all of that only one particular item truly fell into a lack. And it was a Smith’s health-related pediatric respiration tube.

But now still, to this day, a lot of our professional medical gadgets are staying supplied to this incredibly bottleneck sterilization process. And though we are turning into far more educated about, you know, these damaging consequences of ethylene oxide on communities who are uncovered to it, healthcare companies are also keenly attuned to these potential item shortages. And so as we determine out what we are going to do next, I believe healthcare suppliers are actually looking at that, in particular as the EPA moves to launch some proposed principles all-around EtO later on this calendar year. But But what do you think Alex, you are you are the operations and source chain man. How huge of a function does ethylene oxide in fact play here?

Alex Kacik: So yeah, to your position, there is so quite a few areas of healthcare that was touched by the sterilization system, you know, not just surgical resources, but PPE in some cases is sterilized with ethylene oxide. But all round, about half of health-related products utilised in the U.S. are nevertheless sterilized with EtO. It is a reasonably affordable procedure that conveniently penetrates expert services, building it an desirable decision for system makers. Overall health units usually seem to slash fees from the offer chain. So when they cope with items like labor shortages that’s heading on suitable now. Reimbursement reductions are new laws generally look to the offer chain to check out to help save some money. That typically leads them to the most affordable value solution for matters like PPE, prescription drugs and materials, although like you claimed, the COVID-19 pandemic seriously up ended anything illustrated how go into the cheapest price provider, still left them especially susceptible. So a letter from 16 condition lawyers and this gets to the position of your state by state laws, prepared in 2020 cited that 2016 EPA assessment that the cancer possibility of inhaling EtO was 30 occasions larger than beforehand estimated. They wrote that ethylene oxide is amongst the most hazardous air pollutants posing the greatest well being challenges in the premier variety of city locations in the nation. If that led to the closure of some facilities, and that when you stated the respiration tubes, it was traced back again to in suburban Illinois, the Attorney Common pressured Sterigenics to close a sterilization plant, adhering to, you know, residents well being issues.

Sterigenics purchased to pay $363M about exposure to toxic gases

So, Kara, I was hoping you could communicate extra about the condition responses you pointed out: Illinois, Georgia and Michigan that have cracked down on EtO emitters. What do you come across out? And how are the polices transforming?

Kara Hartnett: Yeah, so individuals states ended up kind of the leaders in regulating EtO early on. For them, it generally began, like you reported, with a lawsuit by the Condition Attorney General’s that led to further more investigations by their condition environmental companies, just for instance. So the conclusions of these investigations had been really definitely intriguing, and it aided form a whole lot of what we recognize about ethylene oxide currently. So in advance of all of this, the primary concern bordering publicity to ethylene oxide was actually directed at staff inside these facilities. You know, you see these individuals outfitted with hazmat satisfies and all of these levels of safety to protect them from ethylene oxide as they’re heading by way of that sterilization course of action. But what these investigations actually identified is that ethylene oxide also leaks into the air of the encompassing communities from the sterilizer structures themselves, or by means of some thing known as fugitive emissions.

So in Georgia, for example, they located EtO emissions inside a warehouse where by gadgets had been taken right after being sterilized. Suggesting that the chemical lingered on the units and was now currently being admitted in a spot that doesn’t have related emission safeguards that the sterilizer facilities would have. So all of this has definitely led to stricter emissions controls. And those people states and other states, like California, have also instituted those restrictions. And it requires more levels of engineering on the manufacturers aspect to be capable to kind of keep track of and contain these emissions. And all of this is probable to advise the upcoming EPA rule as properly.

And all of these new rules on ethylene oxide emitters are coming when demand for health care equipment and materials is poised to grow as the population ages. What do you assume the outlook is in conditions of demand from customers here?

Alex Kacik: So the backdrop is that people today are getting older, specifically in the U.S., and they’re going to have to have a lot more health care solutions. So with that, they are going to need more materials and products, the world wide healthcare unit and supplies industries are predicted to maximize by a lot more than 5{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} a yr by means of up till 2030. So involving 2020 and 2030, by yourself, the number of more mature adults in the U.S. is projected to boost by almost 18 million. This suggests by 2031, in five People in america is projected to be 65 yrs old and more than. You will find a massive press listed here to obtain choices to ethylene oxide, as you’ve got penned about. And that being said, you know, health care programs are protecting of, you know, these supply sources. And this has definitely kicked into overdrive all through the pandemic, they actually experienced to scramble on a small time period basis to locate sources for PPE. Some kinds of pharmaceuticals, when global variety of delivery routes shut down, and transport was thwarted. So I visualize, you know, they’re looking for backup supplies. Now, as you know, some of these sterilization plants both have had to shut or, you know, quickly shut down to improve their processes. There has been some speak about hydrogen peroxide, for occasion, which is generally stated as an option for the reason that it is really a quite fantastic germ killer. Challenge is it hasn’t been made use of ahead of to sterilize big batches or fleets of equipment, which is the key difficulty here. How do you discover one thing successful and effective that can make certain these equipment and supplies are cleaned on a large basis at a massive scale?

So, Kara, what do you uncover out in phrases of alternatives to ethylene oxide?

Kara Hartnett: Yeah, you’re completely correct. And this is like, this sort of an vital concern truly will get to the heart of the difficulty below, mainly because the answer will change dependent on who you inquire. But I assume that my respond to is yes, there are solutions, but none still that can arrive at the scale that ethylene oxide can. So, you know, we depend on ethylene oxide the way we do because it truly is pretty successful. It makes it possible for companies to sterilize truckloads of items all at a single time. And it works across most all materials that are made use of. So for instance, manufacturers can can pre-deal surgical kits that consist of metal, paper and plastic and ethylene oxide can sterilize all of those people items at after at a grand scale. And none of our choices in participate in are very there but.

So a further matter that folks who are involved about the provide chain want to see an alternate that can be utilised with the existing engineering and infrastructure. So switching the way we deal and sterilize products will consider a lot of cash. And it really is risky in the present-day provide chain, as you pointed out, but which is what it would take with some of the possibilities that we are at this time looking at. As considerably as what individuals options are, you know, you talked about hydrogen peroxide, you also see people applying gamma radiation, for case in point.

The Food and drug administration is conducting a pilot program on a new sterilization technological know-how with an purpose to reduce EtO use and also come across a feasible different. They have not been equipped to uncover a substitute however, but they have been capable to cut down emissions from about 30{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of the amenities that they are operating with. And they are executing that by encouraging folks to: One particular, transfer products that can be sterilized utilizing a distinct method to actually do that. And by basically changing the concentration of EtO in fact applied in the method. So it turns out that it’s safe and sound to essentially use a minimal fewer EtO than what we have been using ahead of. But that’s the place we stand so far as locating a various alternative.

Not a Contemporary Healthcare subscriber? Indication up right now.

Alex Kacik: And this is the principal component of your conquer. So I wanted to make confident I touched on on this. When you might be hunting at the EtO emitters, what are the prospective wellness fairness problems listed here? You know, you have the possibility of most cancers that’s more substantial than what was initially believed. But you know, also these EtO vegetation are a lot of of which are are in very low money neighborhoods. So what are the impacts there? In phrases of the health equity paradigm?

Kara Hartnett: Yeah, fully. So I truly see a lot of environmental justice concerns with new sterilizers that are becoming produced. So definitely, you know, we have talked about we are in this really tight source condition, and these most important manufacturers want to expand their functions to meet desire. Well, they’re also now functioning in a patchwork regulatory surroundings. And they’re finding the areas that they have the the very least resistance that will value them the least amount of income and will be the best to established up store in.

So this form of goes back again to how I found the tale. Basically, it was it was talking to a public health and fitness professor at the College of Arizona, Paloma Beamer. And she instructed me about a project pending to build a sterilization facility in Tucson, Arizona. So I did some digging, and I discovered that that facility was heading to in fact be positioned in an environmental justice group. So because this details indicated, you know, a good deal of poverty there tons of individuals of shade, there’s also a person of the nation’s oldest Superfund web sites. It really is wherever a armed service contractor dumped degreaser into the land and polluted their drinking water. They also have power crops and airport boneyard about 50 {08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of the county’s major polluters are situated there. And it truly is an region that just commonly has been desecrated by governing administration and business air pollution. And so when the local community found out about strategies to create the sterilizer in their local community, they ended up adamantly opposed to it. I listened to town halls where citizens cited these previous instances and in Illinois, Ga and Michigan, and so they didn’t want to conclusion up like them. They claimed matters like, you know, this wouldn’t be authorized in California. And so why would we permit it right here? And that genuinely resonated. And so I spoke with a Pima County Supervisor there, who explained fundamentally, most of the community authorities was opposed to the challenge and tried to battle it. But they in essence have their hands tied. The facility achieved all of the air top quality criteria. And point out regulation in Arizona truly forbids that criteria from currently being any stricter than the federal criteria, which have not been up to date since 2006.

So not like in destinations like California, Illinois, and Michigan that can go outside of them. Arizona suggests, you know, we just have to adhere with federal polices. And so these new developments are sort of figuring out those people spots. And this craze just keeps playing out. And so in other new sterilizer, for example, is likely in Tijuana, Mexico to serve the Southern California sector. You will find a web page heading in in rural Arkansas, that is viewing a lot of community backlash suitable now. Puerto Rico is one more. The EPA just place out a checklist of the leading EtO emitters in the nation. And there are 4 in Puerto Rico by itself, and there was just 23 on the record. So they choose up just an outsized part of our EtO emissions.

So yeah, there are large environmental justice issues in this article. And these issues are seeping into the partnership these communities have with the health care industry at substantial. And I feel just frequently, from the men and women that I talked to, they just come to feel seriously disposable.

Alex Kacik: Puerto Rico’s appealing, also, I signify, all through soon after Hurricane Maria a number of yrs ago, you know, that messed up all of the intravenous answer, like baggage and some of these sterile injectables, and it sent like the provide chain into a tailspin. So I mean, that’s what’s genuinely intriguing. I signify, so much in a great deal of our provide chain hinges on Puerto Rico and how fragile the infrastructure is there.

Medical device, drugmakers evaluate operations just after Hurricane Fiona

But I was hoping you could make clear a tiny bit in phrases of the transforming EPA restrictions these are forthcoming. What are the suppliers and other stakeholders in the industry anticipating, you know, as these new regulations get hold? What do they entail?

Kara Hartnett: Yeah. So when I talked to people today to attempt to get their grand predictions, they were incredibly hesitant. A person for the reason that the EPA has not ruled on any of this considering the fact that 2006. But also two since they are working with an difficulty that has true implications for the healthcare field. And that’s not a place that they’re typically at, it has possible to genuinely disrupt operations and guide to product or service shortages. And so I think when I talk to healthcare providers about how they want to see this to be solved? They want to see coordination among the EPA, the Food and drug administration, the CDC, the HHS, all of these entities to ensure that there is small disruption.

As much as what the EPA is likely to do. They did a know-how review previously this calendar year, just to kind of see of all the amenities out there, what form of emission controls they have now. In Tucson, where by the permit for that facility was in the end approved. The EPA put a comment demanding them to set up new ongoing checking technological know-how, which basically aids them evaluate in actual time how significantly EtO they are putting out into the air. So they can see a leak as it comes about and be capable to resolve it and minimize emissions that way.

So I believe those are all clues as to the place the EPA will go. I really don’t believe anyone is expecting an all out ban of EtO emissions at this stage, I assume that there is heading to have to be, you know, options that can be scaled into put before they go there. So it appears to be like they are really just likely to be pushing new engineering and emission handle and currently being capable to minimize individuals emissions, while also type of educating the communities wherever these operations are getting place as what is actually heading on and what their threat is. So it is really sort of twofold. But I think that’s wherever we are going to close up is just getting equipped to control and keep an eye on people emissions much better than what we can now.

Alex Kacik: It is really really attention-grabbing. Hey Kara, I am thrilled to see what else you dig up listed here. As you continue on to stick to this. I know. Yeah, we are going to be fascinated to see on these new laws, how these new regulations arrive about and how the field will adapt. So in the meantime, thank you for coming on.

Kara Hartnett: Yeah. Many thanks for obtaining me.

Alex Kacik: All ideal. And thank you all for listening. You can subscribe to Outside of the Byline on Spotify, Apple podcasts or where ever you opt for to pay attention. You can assist the reporting of Kara, of myself and our group of reporters by subscribing to Modern day Healthcare and giving us a follow on Twitter and LinkedIn. Thank you for your assist.

Down load Fashionable Healthcare’s app to continue to be knowledgeable when industry news breaks.

Medical device makers see little impact from Fiona on Puerto Rico operations

Medical device makers see little impact from Fiona on Puerto Rico operations

Sign-up now for No cost unlimited obtain to Reuters.com

Sept 23 (Reuters) – Clinical device organizations and some drugmakers with production operations in Puerto Rico mentioned they do not be expecting significant disruption from Hurricane Fiona, which knocked out power for more than 3 million individuals and triggered flooding and landslides on the island.

The U.S. Food and Drug Administration, which labored with businesses to prevent shortages of medicines and clinical gadgets immediately after Hurricane Maria battered the medical producing hub in 2017, said it is in dialogue with businesses it regulates there concerning any effect on materials.

Most organizations Reuters spoke to, such as Baxter Intercontinental (BAX.N), stated they experienced to begin with both quickly halted functions or were being managing their crops on turbines considering the fact that Fiona struck on Sunday.

Sign-up now for Cost-free endless entry to Reuters.com

None mentioned they expected materials to the United States to be significantly disrupted by the storm, in aspect because of to infrastructure adjustments, these types of as making up their generator electrical power, subsequent Hurricane Maria.

The electric power grid on the island is owned by bankrupt state-operate Puerto Rico Electric Electricity Authority (PREPA) and is now operated by LUMA Electricity, a non-public joint venture of Canadian electrical power business ATCO Ltd and U.S. strength contractor Quanta Services (PWR.N).

Although the pace of ability restoration has been considerably more rapidly than pursuing the devastation of Maria, an believed 1 million houses and enterprises continue being with no electricity.
Baxter, which tends to make little bags for intravenous treatment, scientific nourishment items and inhaled anesthetics in Puerto Rico, stated its amenities have “sustained minor to no problems” from the storm.

By Thursday, Baxter had restarted functions and was functioning at regular, pre-hurricane concentrations, spokesperson Lauren Russ mentioned.

The company took a $70 million earnings hit soon after Hurricane Maria in 2017, spurring it to diversify producing of crucial merchandise.

Ahead of hurricane time, the company now builds up supplies of some products and suppliers a lot of it on the U.S. mainland, Russ claimed, including that Baxter experienced great stock levels for most products and solutions created in Puerto Rico and the Dominican Republic for U.S. consumers.

Integra Lifesciences (IART.O) and Abbott Laboratories also upgraded back again-up turbines and interaction capabilities and shored up infrastructure at plants these kinds of as enhancements to roofs and pipes, their spokespeople stated.

“Most MedTech businesses are far more prepared with better redundancy” than when Maria hit, J.P Morgan analyst Robbie Marcus in a research note.

Spokespeople for other professional medical gear companies like Becton Dickinson (BDX.N), Medtronic (MDT.N), Edwards Lifesciences (EW.N) and Stryker (SYK.N) also claimed they had been not seeing a key influence to operations from Hurricane Fiona thanks to steps carried out next Maria.

Drugmakers with vegetation in Puerto Rico claimed they have been ready to preserve up output and supplies as well.

Johnson & Johnson (JNJ.N) explained operations had been restored at all its websites in Puerto Rico by Wednesday.

AbbVie’s (ABBV.N) services are intact and operational and unlikely to see any affected person effect or solution shortages because of to Fiona, in accordance to a particular person familiar with the company’s operations who questioned not to be named.

Eli Lilly and Co has not skilled any disruptions to its web page or provide, spokesperson Molly McCully reported.

Sign up now for No cost endless entry to Reuters.com

Reporting by Leroy Leo and Khushi Mandowara in Bengaluru further reporting by Michael Erman modifying by Caroline Humer and Monthly bill Berkrot

Our Criteria: The Thomson Reuters Have confidence in Ideas.